Cargando…

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation

Here, we report the identification of key compounds that effectively inhibit the anchorage-independent growth and propagation of cancer stem cells (CSCs), as determined via screening using MCF7 cells, a human breast adenocarcinoma cell line. More specifically, we employed the mammosphere assay as an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonuccelli, Gloria, Sotgia, Federica, Lisanti, Michael P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792210/ https://www.ncbi.nlm.nih.gov/pubmed/36455875 http://dx.doi.org/10.18632/aging.204412

Ejemplares similares

Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production
por: Fiorillo, Marco, et al.
Publicado: (2020)

Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling
por: Peiris-Pagès, Maria, et al.
Publicado: (2018)

Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
por: Bonuccelli, Gloria, et al.
Publicado: (2018)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2019)

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase
por: Fiorillo, Marco, et al.
Publicado: (2021)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
por: Bonuccelli, Gloria, et al.
Publicado: (2016)

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
por: Fiorillo, Marco, et al.
Publicado: (2016)

Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity
por: Sánchez-Alvarez, Rosa, et al.
Publicado: (2020)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2017)

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
por: Sotgia, Federica, et al.
Publicado: (2018)

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy
por: Ozsvari, Bela, et al.
Publicado: (2017)

Antibiotics that target mitochondria extend lifespan in C. elegans
por: Bonuccelli, Gloria, et al.
Publicado: (2023)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting “stemness”
por: Bonuccelli, Gloria, et al.
Publicado: (2017)

Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2013)

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
por: Ozsvari, Bela, et al.
Publicado: (2017)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer
por: Yang, Liyan, et al.
Publicado: (2021)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and Metastasis
por: Larzabal, Leyre, et al.
Publicado: (2013)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
por: Nishikawa, Shigeto, et al.
Publicado: (2023)

Cancer stem cells (CSCs): metabolic strategies for their identification and eradication
por: De Francesco, Ernestina M., et al.
Publicado: (2018)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae
por: Li, Tingting, et al.
Publicado: (2019)

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2018)

The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides
por: Lei, Xiling, et al.
Publicado: (2015)

Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
por: Hou, Zhi-Jie, et al.
Publicado: (2015)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

Cancer Metabolism: New Validated Targets for Drug Discovery
por: Sotgia, Federica, et al.
Publicado: (2013)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
por: Choi, Ha Yeong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i0idkt5d86adu0oumr7ap3pvp5